Matters of the Heart

Your destination for today’s heart health conversation.

Misdiagnosis is a Top Concern of Cardiac Patients

Despite many recent advances in cardiovascular diagnosis and treatment, misdiagnosis is still a common concern for patients at risk of heart disease, the leading cause of death in the United States. A complex web of symptoms, circumstances and comorbidities means that it’s not always easy for physicians to correctly identify conditions on the first visit.

Take Control of Your Health with New Technologies

In the last few years, we’ve seen an explosion in consumer health devices, from watches that monitor your heart rate to apps that track everything from sleep to blood pressure to calories. However, various misconceptions, anxieties and fears still keep patients from talking openly with their doctors, particularly when it comes to heart disease. Learn how technology can help not hinder the quality of healthcare you receive.

Read More

Misdiagnosis is a Top Concern of Cardiac Patients

Using coronary computed tomography angiography (CCTA) with HeartFlow’s FFRCT Analysis to evaluate suspected coronary artery disease offers higher diagnostic accuracy, fewer unnecessary tests and higher confidence in identifying patients needing treatment.

Read More

Take Control of Your Health with New Technologies

In the last few years, we’ve seen an explosion in consumer health devices, from watches that monitor your heart rate to apps that track everything from sleep to blood pressure to calories. However, various misconceptions, anxieties and fears still keep patients from talking openly with their doctors, particularly when it comes to heart disease. Learn how technology can help not hinder the quality of healthcare you receive.

Read More

The HeartFlow Analysis has the highest accuracy compared to other non-invasive tests1 and has been proven to reduce the number of unnecessary tests and procedures.2

Learn what other tests lack and why the HeartFlow Analysis sets a new standard of care.

The patient journey to a coronary artery disease (CAD) diagnosis can be long and challenging, but it doesn’t have to be. Learn more about the pros and cons of traditional diagnostic tests and how the HeartFlow Analysis offers a more streamlined process.

We conducted a survey of more than 1,500 adults in the U.S. and uncovered misconceptions about the leading cause of death in men and women, as well as a shared positive outlook on innovations in healthcare that will help transform the diagnosis and treatment of heart disease.

Learn more in our infographic.

Previous slide
Next slide
  1. Douglas, et al. J Am Coll Cardiol 2016.
  2. Driessen, et al. J Am Coll
    Cardiol 2019; Norgaard, et al, Euro J Radiol 2015.

Sign Up For Updates

* Required Fields

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.

本情報は日本国内の医療関係者を対象とした情報提供サイトです。
一般の方に対する情報提供を目的としたものではございません。
あなたは医療関係者ですか?